RTP Mobile Logo
Select Publications

Chaft JE. IO in the surgical resectable patient. IASLC 2021;Abstract PL05.04. 

Farid S, Liu SV. Chemo-immunotherapy as first-line treatment for small-cell lung cancer. Ther Adv Med Oncol 2020;12:1758835920980365. Abstract

Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-57. Abstract

Girard N et al. PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. ESMO 2021;Abstract 1171MO.

Gogishvili M et al. EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). ESMO 2021;Abstract LBA51.

Herbst RS. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 2020;383(14):1328-39. Abstract

Jabbour SK et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, Stage III non–small cell lung cancer: The Phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol 2021;7(9):1351-9. Abstract

Jonna S et al. Effect of prior therapy on tumor mutational burden in NSCLC. Transl Lung Cancer Res 2021;10(3):1231-8. Abstract

Liu SV et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 2021;39(6):619-30. Abstract

Montenegro GB et al. Immunotherapy in lung cancer. J Surg Oncol 2021;123(3):718-29. Abstract

Paz-Ares L et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. Ann Oncol 2021;32(suppl 5):S1283-46;Abstract LBA61.

Paz-Ares L et al. Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. ASCO 2021;Abstract 9016.

Paz-Ares L et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 2020;15(10):1657-69. Abstract

Reck M et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. ASCO 2021;Abstract 9000.

Reuss JE et al. Antibody drug conjugates in lung cancer: State of the current therapeutic landscape and future developments. Clin Lung Cancer 2021;22(6):483-99. Abstract

Rodríguez-Abreu D et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: Protocol-specified final analysis from KEYNOTE-189. Ann Oncol 2021;32(7):881-95. Abstract

Rodriguez-Abreu D et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). ASCO 2020;Abstract 9503.

Sezer A et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 2021;397(10274):592-604. Abstract

Socinski MA et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol 2021;16(11):1909-24. Abstract

Spicer J et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8503.

Spigel DR et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. ASCO 2021;Abstract 8511.

Taylor MH et al. The LEAP program: Lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Futur Oncol 2021;17(6):637-48. Abstract

Taylor MH et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 2020;38(11):1154-63. Abstract

Wakelee HA et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8500.